title: Immune Checkpoint Inhibitors for Urologic Cancer: The Tip of the Iceberg?
authors: Experimental Cancer Medicine Centre, Barts Cancer Institute, Barts Health and the Royal Free NHS Trust, Queen Mary University of London, London EC1A7BE, UK. Electronic address: thomas.powles@bartshealth.nhs.uk.
authors: Tom
authors: T
authors: Powles
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors*; D059951:HLA-G Antigens; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016246:Lymphocytes, Tumor-Infiltrating / Q000187:drug effects*; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D013601:T-Lymphocytes / Q000187:drug effects*; D014571:Urologic Neoplasms / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; D059951:HLA-G Antigens; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor